DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
TRASTYVERE
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
BREAST
(Journal) Clinical and Translational Oncology
2019
MERIBEL
Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2[-] metastatic breast cancer: The MERIBEL Study
BREAST
(Journal) Clinical Breast Cancer
2019
TRANSFAL
Baseline and pharmacodynamics changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis from the PARSIFAL trial
BREAST
SABCS
2019
SLLIP
Use of comprehensive cell-free circulating tumor DNA analysis to identify genomic biomarkers in newly diagnosed advanced non-small cell lung cancer patients
LUNG
AACR
2019
PALMIRA
Palociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer : The PALMIRA trial
BREAST
ESMO
2019
DXCARTES
Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX recurrence score*(RS) 18-25 or 26-100. Analyisis of RS changes at surgery (DXCARTES trial)
BREAST
AACR
2019
NOBROLA
A two-stage simon design phase II study for non-BRCA metastatic breast cancer (MBC) patients with homologous recombination deficiency treated with olaparib single agent (NOBROLA study)
BREAST
AACR
2018
KELLY
A phase II study of pembrolizumab and eribulin HR-positive/HER2-negative metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes (KELLY study)
BREAST
AACR
2018
SLLIP
Homology-directed repair (HDR)-defective lung adenocarcinomas in circulating tumor DNA (ctDNA)
LUNG
ESMO
2018
PHENOMENAL
Multicenter open-label, phase II trial to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastatases in patients with HER2-negative breast cancer (The Phenomenal study)
BREAST
AACR
2018
SLLIP
Cell-Free DNA (cfDNA) testing in lung adenocarcinoma (LUAC) patients: Spanish Lung Liquid versus Invasive Biopsy Program (SLLIP)
LUNG
IASLC
2018
EXCAAPE
Phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)
PROSTATE
ESMO
2017
Other MEDSIR related articles
